Haystack MRD® is an advanced tumor-informed minimal residual disease (MRD) test that detects ctDNA in blood with exceptional sensitivity and specificity.
Baltimore, MD
Joined June 2022
- Tweets552
- Following31
- Followers139
- Likes52
Haystack MRD® by Quest Diagnostics® retweeted
A significant milestone for Haystack MRD® by Quest Diagnostics® and the patients we serve. With New York State approval, @HaystackMRD is now available in all 50 U.S. states, helping expand access to advanced cancer monitoring. newsroom.questdiagnostics.co…
Haystack MRD® by Quest Diagnostics® retweeted
This week, Mark Gardner, SVP of Genomic Medicine & Oncology, & Dan Edelstein, President and CEO of @HaystackMRD, sat down with @AdvisoryBd guest host Devin Airey to share their vision for #genomics at scale. Click for the full #RadioAdvisory episode.
link.chtbl.com/Episode174?si…
Haystack MRD® by Quest Diagnostics® retweeted
Huge thanks to @Anchor_Ventures for helping us host such an excellent event featuring Dan Edelstein, Daniel Lunz & Victor Velculescu sharing their experiences as founders/CEOs of cancer diagnostics startups in Baltimore!
Haystack MRD® by Quest Diagnostics® retweeted
We will not stop putting our flags into the ground until our elected officials prioritize #colorectalcancer. We don’t have time to wait.
United in Blue is a visual reminder that by 2030, colorectal cancer is expected to be the No. 1 cause of cancer death for those under the age of 50. Honor a loved one today: Fightcolorectalcancer.org/tr…
Haystack MRD® by Quest Diagnostics® retweeted
Today, colorectal cancer survivors, caregivers, and advocacy partners nationwide collaborated to create awareness alongside @FightCRC for United in Blue, a flag installation on the National Mall.
This is a visual reminder that by 2030, colorectal cancer is projected to be the number one cause of cancer deaths for those under age 50.
But together, we can raise the necessary awareness needed to end this disease in our lifetime.
#ColorectalCancerAwarenessMonth
Haystack MRD® by Quest Diagnostics® retweeted
.@HaystackMRD is gearing up to launch its personalized liquid biopsy test for minimal residual disease detection this year. An Emerging Company Profile by BioCentury's Richard Guy (@NTAPGuy) buff.ly/3xh6oJs
Haystack MRD® by Quest Diagnostics® retweeted
Congratulations to JHU startup @HaystackMRD for achieving an important milestone to advance early-stage cancer diagnostics! Learn more bddy.me/3GlCtFH
Haystack MRD® by Quest Diagnostics® retweeted
STAT+: Thrive founders launch new blood testing startup to spot when cancer returns trib.al/hg8BLyk
Haystack MRD® by Quest Diagnostics® retweeted
DYNAMIC: Among patients with stage II colon cancer, a ctDNA-guided management approach reduced the use of adjuvant chemotherapy without increasing the risk of recurrence. #ASCO22 nej.md/3x0jR94
Haystack MRD® by Quest Diagnostics® retweeted
Stage II post-op #crcsm #ctDNA DYNAMIC trial, beginning of prospective data we’ve waited for: substantially reduced adjuvant chemo by nearly 50% w/o compromising 2-yr RFS in ctDNA-guided approach vs. SOC (40% high-risk St II in both) #ASCO22 same-day NEJM nejm.org/doi/full/10.1056/NE… – at Chicago, IL
Haystack MRD® by Quest Diagnostics® retweeted
4. #DYNAMIC: ctDNA used to guide adj Rx in Stage II CRC, Ph 2, N=455
- ctDNA approach decreased use of adj chemotherapy (15% Vs. 28%) without comprising RFS
- 3 yr RFS was 86.4% in ctDNA-positive pts who received adjuvant chemo Vs. 92.5% in ctDNA-negative pts who did not
5/5
Haystack MRD® by Quest Diagnostics® retweeted
We’ve been overtreating some patients with stage II #colorectalcancer with unnecessary adjuvant chemo for too long: carefully monitor those who’re ctDNA negative - Circulating Tumor DNA Analysis Guiding Adjuvant Therapy @NEJM @ASCO #ASCO22 @RueschCenter nejm.org/doi/full/10.1056/NE…
Haystack MRD® by Quest Diagnostics® retweeted
Once again, less is more (non-inferior while sparing patients needless toxicity!)
"In this trial, we found that a ctDNA-guided approach reduced the number of patients who received adjuvant therapy and did not alter the risk of recurrence”
#crcsm #ASCO22
nejm.org/doi/full/10.1056/NE…
Haystack MRD® by Quest Diagnostics® retweeted
#ASCO22
✳️DYNAMIC trial results are highly exciting and glad to see field is moving forward !
✳️Very encouraging findings that we are in right pathway to use #ctDNA for adjuvant tx‼️
However there are important points that we need to address 👇@asco @OncoAlert @MoffittNews
Haystack MRD® by Quest Diagnostics® retweeted
WoW. Absence of ctDNA post surgery decreases by 2 the use of adjuvant chemo in pts with stage II colon cancer. First randomized trial showing that MRD (minimal residual disease) may help to de-escalade! #ASCO22 & nejm.org/doi/full/10.1056/NE…
Haystack MRD® by Quest Diagnostics® retweeted
#ASCO22- Plenary-worthy DYNAMIC RTC results show ctDNA- informed management of Stage2 #coloncancer reduces adjuvant chemotherapy use (28vs15%) without adversely affecting RFS, non-inferiority met. Congrats Dr.Tie! @NEJM @pashtoonkasi @ChilesResearch
